Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Journeytcon Mar 15, 2024 2:07pm
281 Views
Post# 35935359

What's Next

What's NextMy take.  Things begin to swing in a good direction in a permanent way in May and maybe before. 

ONC waits for ADC outcomes to evolve and primary investigators of ADC treatments to report results at conference. ONCs planned review by key performance leaders can only occur at this moment when updated ADC data and Bracelet data are available for contrast.  
Once the key performance leaders review is complete,  ONC can define the target Breast Cancer patient population.  We know this became an issue for them last year after Bracelet data published. I think ADC result will be reported at April's AACR meeting?   Apologies if not. 

Will pela target the entire HER2- population or will it target the population coming off ADC treatments.  That is the question!
ONC can and will file for a phase 3 application with this clarity.
ONC is a breast cancer company!   Potential risked revenues are so much greater than other opportunities.  The population is so much larger.   And Pela is administered with less expensive drugs not ICIs. 

The market will respond in spades like it started to last year before getting derailed.  The market awaits application and launch of the phase 3 breast cancer trial.  
<< Previous
Bullboard Posts
Next >>